Book summary “A Crack in Creation”: summary

Introduction

You live in a time when humanity is shifting from the passive subject of blind evolution to the active architect of biological destiny. For decades, you watched genetic diseases devastate families and diseases spread unchecked because you lacked the tools to rewrite the fundamental code of life.

Jennifer A. Doudna and Samuel H. Sternberg reveal how curiosity-driven research into bacterial immune systems unlocked a programmable molecular scissors known as CRISPR-Cas9. The book chronicles the race to harness this technology, showing how it transforms basic biology into an engineering discipline capable of curing hereditary illness, revolutionizing agriculture, and altering human germlines.

You will discover how this immense power forces an urgent moral reckoning over who decides which traits survive. The book addresses fundamental questions about this biological revolution.

• How do bacteria defend themselves against viral invaders using memory-based immunity?
• What mechanisms allow researchers to program molecular tools to cut specific DNA sequences?
• Where do we draw the line between treating disease and enhancing human traits?

1. The Quest for a Cure

Hereditary diseases stem from minute letter mutations in DNA, and historical attempts to fix them through early gene therapies and designer nucleases laid the technical groundwork for modern genome editing.

Genetic information flows from DNA to RNA to proteins, and simple letter mutations in DNA can cause severe, life-threatening hereditary diseases. The human genome contains 3.2 billion letters of DNA and 21,000 protein-coding genes. Out of that vast sequence, 4,000 DNA mutations are known to cause genetic disease.

In sickle cell disease, a single letter mutation in the beta-globin gene changes glutamate to valine, causing hemoglobin molecules to stick together and distort red blood cells.

Genetics Fundamentals and Natural Repairs

Rare cases of natural spontaneous recovery from genetic diseases demonstrate that cells can sometimes fix damaged DNA on their own. Through phenomena like chromothripsis or spontaneous repair, a diseased cell can eliminate a harmful mutation and regenerate healthy daughter cells, though the odds of this happening naturally are extremely low.

A patient named Kim, diagnosed with WHIM syndrome, experienced a spontaneous cure when a single hematopoietic stem cell underwent chromothripsis, deleting the mutated CXCR4 gene and repopulating her immune system with healthy white blood cells. Scientists at the NIH examined Kim and her daughters in 2013, when Kim was 58 years old. They found that a section of chromosome 2 missing in Kim's blood cells spanned 35 million letters and 164 genes, out of the 6 billion total letters in human DNA.

Pioneering gene therapies attempted to use modified viruses as delivery vectors to insert therapeutic genes into human cells. Viruses naturally possess efficient mechanisms for infiltrating cells and splicing genetic material, leading researchers to turn them into Trojan horses for delivering healthy genes, though early trials faced safety and efficacy issues. Remnants of ancient retroviruses make up 8 percent of the human genome. By 2016, researchers had completed or initiated 2,000 gene-therapy trials.

In the 1970s, physician Stanfield Rogers attempted to treat hyperargininemia in two German girls by injecting purified rabbit Shope papillomavirus, but the therapy failed.

Designer Nucleases and Double-Strand Breaks

Inducing a precise double-strand break in the DNA greatly increases the efficiency of homologous recombination and gene editing.

Cells possess a natural mechanism called homologous recombination that allows them to precisely swap out old DNA sequences for matching new ones. Mario Capecchi and Oliver Smithies discovered that homologous recombination occurs in mammalian cells. This lets cells integrate lab-made DNA templates into matching chromosomal locations, forming the foundation of gene targeting. In 1982, Mario Capecchi published an article suggesting exploiting enzymes for gene targeting, despite facing an early ratio of 100 to 1 for illegitimate recombination over homologous recombination.

Oliver Smithies and his colleagues successfully replaced the beta-globin gene in human bladder tumor cells with an artificial recombinant version using calcium phosphate.

Jack Szostak published the double-strand-break model in 1983, proposing that a double-strand break acts as an alarm initiating repair by matching chromosomes. Maria Jasin proved that introducing a specific endonuclease to make a targeted cut dramatically raises the rate of precise gene repair. In 1994, Maria Jasin used the yeast I-Sce I endonuclease, which requires 18 consecutive DNA letters for recognition, to induce a double-strand break in mouse cells, achieving a 10 percent rate of precise gene repair.

To make gene editing programmable, scientists engineered chimeric nucleases by combining DNA-recognition modules with non-specific cutting enzymes. Srinivasan Chandrasegaran presented his chimeric nuclease study in 1996, fusing the cutting module of the FokI bacterial nuclease with zinc finger proteins to create zinc finger nucleases. Researchers later complemented zinc finger nucleases with more easily programmable transcription activator-like effector nucleases derived from plant pathogens, following the 2009 discovery of transcription activator-like effectors.

In 2003, Matthew Porteus and David Baltimore showed human cell editing using custom-built zinc finger nucleases. Dana Carroll's lab used zinc finger nucleases to target the yellow gene in fruit flies, producing precise genetic alterations in a whole organism.

2. Cracking the Code

In the 1990s, Doudna determined the three-dimensional structure of a self-splicing ribozyme, hoping these RNA molecules might eventually serve as tools for editing DNA and repairing genetic defects. Working with graduate student Jamie Cate at Yale, Doudna mapped the precise location of every atom in a self-splicing ribozyme. Although ribozyme-based therapies ultimately did not become effective tools for treating genetic diseases in humans, this early work focused her career on the profound therapeutic potential of manipulating genetic material.

Doudna shared a green ink drawing of the ribozyme molecule with her father, who likened it to green fettuccine shortly before passing away from melanoma.

Bacterial Adaptive Immunity

Bacteriophages are lethal viruses that infect bacteria and represent the most prevalent biological entities on Earth. Phages possess a durable protein exterior called a capsid and infect bacteria via lysogenic or lytic pathways, often causing cells to violently burst open. They have played a foundational role in molecular genetics by helping prove that DNA is the hereditary molecule.

Félix d'Herelle used a fine-sieved filter to remove bacteria from stool samples during a dysentery outbreak in World War I, discovering that the filtered liquid dissolved dysentery bacteria overnight.

There are 10^31 estimated bacteriophages on Earth, and 40 percent of ocean bacteria die daily from phage infections. Today, 20 percent of bacterial infections are treated with phages in Georgia.

CRISPR refers to a specialized region of bacterial DNA consisting of identical repeating sequences interspaced with unique variable sequences. Brought to Doudna's attention by geomicrobiologist Jillian Banfield, CRISPR stands for clustered regularly interspaced short palindromic repeats. The identical stretches of DNA act as repeats, while the interspacing sequences vary uniquely across cells, representing the fastest-evolving regions in the prokaryotic genome.

Jillian Banfield used a notebook at the Free Speech Movement Café to sketch a bacterial cell, its chromosome, and the alternating diamonds and squares representing CRISPR arrays.

Nearly half of bacterial genomes contain CRISPRs, compared with over 50 percent of the human genome comprising repetitive arrays.

Research on milk-fermenting bacteria proved that CRISPR functions as an adaptive immune system allowing bacteria to inherit resistance against specific viruses. Rodolphe Barrangou and Philippe Horvath at Danisco studied Streptococcus thermophilus strains exposed to virulent phages. They discovered that surviving mutant bacteria incorporated new snippets of phage DNA into their CRISPR regions, making the immunity heritable.

Danisco researchers combined Streptococcus thermophilus with two dairy phages in test tubes, finding that nine surviving mutant strains had expanded CRISPR regions matching the phage DNA.

This research supported an annual market value of forty billion dollars for Streptococcus thermophilus cultures, even though 99.9 percent of bacteria were wiped out by phages in the test tube experiment.

Bacteria use CRISPR arrays as a molecular vaccination card by storing memories of past viral infections to recognize and destroy invading phages. By retaining viral spacer sequences within repeat-spacer arrays, the bacterial genome matches invading genetic material to mount a targeted immune response. This mirrors human adaptive immunity in its ability to record and remember specific pathogens.

Blake Wiedenheft joined Doudna's lab as a postdoc after discovering extremophile viruses in Yellowstone and Kamchatka, and immediately initiated biochemical studies on Pseudomonas aeruginosa Cas proteins. His discoveries included novel hot spring viruses tolerating 170 degrees Fahrenheit.

Molecules of RNA act as the guiding agents that coordinate the recognition and destruction phases of the CRISPR antiviral defense. Researchers like Stan Brouns demonstrated that bacterial cells convert entire CRISPR arrays into long RNA strands, which enzymes then trim into shorter functional units. Luciano Marraffini and Erik Sontheimer further proved that these CRISPR RNAs use base-pairing interactions to direct the destruction of invading viral DNA.

Luciano Marraffini worked with Staphylococcus epidermidis to show that CRISPR RNAs target the DNA of invading genetic parasites using base-pairing specificity.

Moving beyond genetics to biochemistry allowed researchers to isolate individual Cas proteins and study their functions as enzymatic molecular cleavers. Blake used Escherichia coli engineered with artificial plasmids to mass-produce Cas proteins. Using fast-spinning centrifuges, salt solutions, and sound waves, cells were ruptured to isolate pure Cas enzymes like Cas1 and Cas6, revealing their roles in cutting DNA and RNA.

Blake engineered Escherichia coli strains to incorporate plasmids from Escherichia coli and Pseudomonas aeruginosa, allowing the mass production and purification of Cas proteins.

Fast-spinning centrifuges apply a force four thousand times greater than the gravity we feel on earth to separate cells from liquid broth.

Type I CRISPR-Cas immunity relies on a multi-protein complex called Cascade for targeting viral DNA and the nuclease Cas3 for destroying it. The Cascade complex, containing ten or eleven Cas proteins, wraps around viral DNA using CRISPR RNA as GPS coordinates. Once the target is marked, Cas3 acts like a motorized hedge clipper, rapidly shredding the phage genome into numerous pieces.

Electron microscopy imaging with Eva Nogales and Gabe Lander revealed the helical architecture of the Cascade machine coiling around viral DNA.

Cas3 shuttles along the phage genome to slice up DNA at a rate of over three hundred base pairs per second. Ten or eleven different Cas proteins make up the Cascade molecular assemblage.

As genome sequencing expanded, scientists discovered that CRISPR systems are remarkably diverse, categorized into multiple types and subtypes with distinct sets of cas genes. Comparison of different microbial genomes showed that CRISPR immunity is not uniform. The classification shifted rapidly over the years as researchers found wide variations in how different bacterial species structure their defense systems.

Eugene Koonin and Kira Makarova predicted variations based on flanking cas genes, showing how classifications evolved from nine different types in 2005 to three basic types by 2011, and finally to two broad classes comprising six types and nineteen subtypes by 2015.

Engineering the Cas9 Tool

By studying bacterial adaptive immunity and combining Cas9 with tracrRNA and CRISPR RNA into a single-guide RNA, researchers transformed a natural defense system into a programmable gene-cutting tool.

A chance meeting in Puerto Rico sparked a crucial transatlantic collaboration focused on unraveling the mystery of the Type II Cas9 enzyme in Streptococcus pyogenes. Emmanuelle Charpentier and Jörg Vogel had discovered a second necessary RNA molecule, tracrRNA, involved in producing CRISPR RNAs. Charpentier proposed joining forces with Doudna to apply biochemical and structural expertise to study the Csn1 protein, later named Cas9.

Jennifer Doudna and Emmanuelle Charpentier met at an American Society for Microbiology meeting in Puerto Rico in the spring of 2011 and collaborated across a ten-hour time zone difference between Umeå University in Sweden and Pacific Standard Time.

The DNA-cleaving activity of the Cas9 enzyme requires both CRISPR RNA and a second RNA molecule known as tracrRNA. Initial test-tube experiments using only Cas9 and CRISPR RNA failed to cut target DNA. When Martin Jinek and Krzysztof Chylinski included tracrRNA alongside CRISPR RNA and Cas9, the DNA matching the twenty-letter sequence was cleanly cleaved.

Martin Jinek and Krzysztof Chylinski performed experiments incorporating tracrRNA, successfully demonstrating RNA-guided double-strand DNA cutting.

The target DNA has a fifty-letter double helix measuring seventeen nanometers or seventeen-billionths of a meter, which is one-thousandth the width of a human hair.

By fusing the CRISPR RNA and tracrRNA into a single chimeric molecule, researchers created a simplified, highly usable programmable DNA-cutting tool. Martin Jinek and Jennifer Doudna reasoned that fusing the tail of one RNA to the head of the other would create a single-guide RNA. This eliminated the need to combine Cas9 with two separate RNA molecules, drastically streamlining the gene-cutting machinery.

Martin Jinek engineered five different twenty-letter sequences within the green fluorescent protein gene from jellyfish to test whether Cas9 could cut non-viral DNA. This followed the 2008 Nobel Prize in Chemistry awarded to Martin Chalfie, Osamu Shimomura, and Roger Tsien for green fluorescent protein.

You can prepare the editing system by following specific procedures:

• Design single-guide RNA molecules by fusing the tail of tracrRNA to the head of CRISPR RNA
• Select target twenty-letter sequences within the desired gene of choice
• Incubate the single-guide RNA with Cas9 and the target DNA in a cleavage assay to break apart the sequence

In June 2012, Doudna and her collaborators formally submitted their landmark paper demonstrating RNA-programmed Cas9 for genome editing to the journal Science. The research article established the mechanism of RNA-guided DNA cleavage by Cas9 and explicitly highlighted its immense potential as an alternative methodology for gene-targeting and genome-editing applications.

Jennifer Doudna submitted the paper on Friday, June 8, 2012, which was published twenty days later on June 28. Prior to this work, only about two hundred scientific articles mentioning CRISPR had been published in the prior decade.

3. Command and Control

CRISPR-Cas9 enables precise somatic edits, gene knockouts via sloppy repair, multiplex animal modifications, and noncutting gene-expression control through deactivated proteins. You gain an unprecedented toolkit to command the genome.

CRISPR-Cas9 can precisely target and repair specific disease-causing genetic mutations in human cells, such as the single-letter mutation responsible for sickle cell disease.

In June 2013, Jennifer Doudna visited Kiran Musunuru's Harvard lab. Kiran Musunuru demonstrated at Harvard University how infusing sickle cell patient blood cells with Cas9, guide RNA, and a healthy beta-globin replacement sequence successfully corrected the genetic defect.

You use this homology-directed repair through specific steps:

• Deliver three CRISPR-related elements: Cas9 protein from Streptococcus pyogenes, guide RNA designed to home in on the mutated site, and a synthetic DNA replacement sequence.
• Target the genome at the mutation site to cut it and mark it for repair.
• Allow the cell to use the healthy replacement sequence to patch up and repair the gene.

Somatic Repair and Knockouts

When CRISPR cuts a gene without a repair template, cells utilize an error-prone repair process that often creates small insertions or deletions, effectively disrupting the gene. Martin Jinek and Jennifer Doudna targeted the human clathrin light chain A gene in human embryonic kidney cells to test CRISPR against older zinc-finger nuclease technology.

You can perform this gene knockout process using standard laboratory techniques:

• Transfer bacterial DNA encoding Cas9 and CRISPR-derived RNA into plasmids.
• Add nuclear localization signal and green fluorescent protein genes to track delivery.
• Mix the plasmids in a soapy solution of lipids to form microscopic greaseballs.
• Add the mixture to cells so plasmids enter the interior and express CRISPR components inside the nucleus.
• Detect successful gene editing by analyzing DNA sequence letter by letter for signs of sloppy repair.

Rudolf Jaenisch's lab at MIT generated gene-edited mice using CRISPR in a one-month protocol, replacing older embryonic stem cell methods that took generations of interbreeding. A University of Texas research team in 2014 study targeting the TYR gene injected CRISPR into fertilized eggs of dark-haired mice, producing white-haired, red-eyed albino pups. A Japanese team later achieved 97 percent efficiency with minor tweaks.

Democratization and Control

By intentionally disabling the catalytic cutting core of Cas9, scientists can transform CRISPR into a noncutting gene-expression controller that turns genes on, off, or dims them. Stanley Qi at UCSF, working with Jonathan Weissman and Wendell Lim, demonstrated that deactivated CRISPR can make temporary changes to gene expression without altering underlying DNA.

You apply deactivated CRISPR through distinct actions:

• Mutate the amino acids of Cas9 that chemically cleave the DNA double helix to create a deactivated, noncutting version.
• Combine deactivated Cas9 or guide RNA with protein payloads.
• Program CRISPR to ferry protein payloads to specific genes to brighten or dim their functional output.

Nonprofit repositories and automated software algorithms have democratized gene editing, allowing researchers worldwide to perform complex experiments cheaply and rapidly. Addgene operated like a Netflix for plasmids, shipping around 60,000 CRISPR-related plasmids to researchers in over 80 countries in 2015 alone for a nominal academic fee.

You access these tools through practical preparation:

• Access advanced software packages that incorporate empirical data and algorithms to design the best version of CRISPR for a given gene.
• Order basic CRISPR-containing artificial plasmids from a repository like Addgene.
• Execute experiments locally using standard laboratory techniques within days.

4. The CRISPR Menagerie

Gene editing revolutionizes agriculture, livestock breeding, and biomedical models by offering precise mutagenesis, disease resistance, and revolutionary gene drives without foreign DNA.

Plant and Animal Engineering

Traditional methods like x-rays, gamma rays, or chemical mutagens pepper the plant genome with hundreds or thousands of random mutations. In contrast, CRISPR enables precise gene knockouts, corrections, or insertions without introducing foreign DNA or unwanted background mutations.

In 2014, scientists at the Chinese Academy of Sciences used CRISPR to alter all six copies of the Mlo gene in bread wheat, creating plants resistant to powdery mildew without harmful side effects from other random mutations. European scientists solved a mystery regarding powdery mildew resistance in barley linked to the Mlo gene in 2004. A German barley cultivar was irradiated with x-rays to induce natural mutagenesis in 1942.

Food scientists can deactivate target genes to eliminate unhealthy fatty acids or prevent chemical reactions that produce dangerous toxins during high-heat cooking, all without introducing foreign genes.

Researchers at Calyxt inactivated a single gene in Ranger Russet potatoes to prevent cold-induced sweetening, resulting in a 70 percent drop in acrylamide levels in chips and no browning. Soybean oil production reaches 50 million tons annually. Processing plants previously discarded 15 percent of potatoes due to cold-induced sweetening browning.

Public perception of genetically modified organisms is often driven by misunderstanding, despite broad scientific consensus on their safety and strict regulatory oversight. While the USDA broadly defines genetic modification to include traditional mutation breeding, popular definitions focus on recombinant DNA and gene splicing. Nearly 60 percent of Americans view GMOs as unsafe.

In 2015, 92 percent of all corn, 94 percent of all cotton, and 94 percent of all soybeans grown in the United States were genetically engineered. The first commercially grown GMO plant approved for human consumption, the Flavr Savr tomato, was introduced in 1994.

Inactivating the myostatin gene using gene editing can replicate natural double-muscling traits, increasing lean meat yield in livestock without altering overall health. The myostatin gene acts as a natural brake on muscle tissue production. Mutations causing defective myostatin proteins occur naturally in certain cattle, sheep, and dog breeds, resulting in exceptional muscle mass.

Belgian Blue cattle are missing eleven letters of DNA in the myostatin gene, while Piedmontese cows have a single-letter mutation, both leading to 20 percent more muscle on average. Three labs determined that a single myostatin gene was responsible for exceptional muscle development in 1997. Gene-edited pigs showed a 10 percent substantial increase in lean meat compared to unedited counterparts.

Gene editing can protect livestock from devastating viral diseases by disabling specific host genes that viruses rely on to hijack cells. By identifying exact genetic differences that confer natural resistance in wild relatives or by knocking out specific vulnerability genes in domestic livestock, scientists can render animals completely immune to lethal agricultural viruses.

Researchers at the University of Missouri used CRISPR to create gene-knockout pigs by inactivating the CD163 gene, making the animals completely healthy and free of PRRSV virus traces after exposure to one hundred thousand viral particles at Kansas State University. The PRRSV virus causes $500 million in annual cost to U.S. pork producers.

Gene editing can ethically eliminate painful agricultural practices by directly copying natural hornless traits into elite dairy cattle. Dehorning millions of calves annually causes significant pain and stress. Thirteen million calves are dehorned every year in the United States.

A Minnesota company called Recombinetics created two hornless dairy calves named Spotigy and Buri by copying a natural genetic change into dairy bulls. A German research team discovered the exact genetic cause of natural hornlessness involving a 10-DNA-letter deletion and 212-DNA-letter insertion in 2012.

Pigs and nonhuman primates can be gene-edited using CRISPR to serve as superior models for human diseases and as a renewable source of organs for xenotransplantation. Mice often fail to mimic hallmark human symptoms for complex diseases. The house mouse and humans share 99 percent of their genes.

Revivicor outlined plans to breed a thousand pigs a year to supply organs, following successful tests where a pig heart was accepted by a baboon's body for two and a half years. There are 124,000 patients currently on the waiting list for organ transplants in the United States, while 28,000 transplants are carried out annually in the U.S. An average of 22 people die daily while waiting for an organ transplant.

CRISPR facilitates de-extinction efforts by allowing scientists to convert contemporary genomes into those of extinct species, raising complex ecological and ethical questions. By sequencing preserved DNA from extinct species, researchers can identify key genetic differences related to cold adaptation or physical traits and sequentially edit modern relative cells to match, though the resulting animal remains a hybrid.

A Harvard research team led by George Church used CRISPR in 2015 to convert elephant cells to woolly mammoth variants for fourteen genes associated with temperature sensation, hair, and fat tissue out of 1,668 differing genes. The elephant and woolly mammoth genomes differ by 1.5 million total DNA letter differences.

Gene Drives and Ecosystems

CRISPR gene drives bypass standard inheritance laws to autonomously copy themselves and spread specific genetic traits through wild populations at exponential rates.

Unlike normal sexual reproduction where a gene has a 50 percent inheritance probability, a CRISPR gene drive cuts DNA and inserts a new sequence that encodes CRISPR itself, allowing it to copy into new chromosomes every generation and achieve near-100 percent transmission. Evolutionary biologist Austin Burt proposed harnessing selfish genes in 2003. Kevin Esvelt's team at Harvard proposed building gene drives with gene editing in 2014.

Ethan Bier and Valentino Gantz demonstrated a CRISPR gene drive in fruit flies and mosquitoes, achieving transmission rates of 97 percent for a yellow-body trait and 99.5 percent for malaria resistance in wild mosquitoes during tests.

Natural Cas9 can occasionally make off-target cuts at mismatched DNA sequences, requiring computational, empirical, and protein-engineering strategies to ensure safety. Because gene edits are irreversible and copied into descendant cells, unintended cuts pose risks. Martin in Jennifer Doudna's lab and David Liu's team at Harvard exhaustively tested mismatched DNA sequences to determine which off-target sites get recognized and cut by CRISPR amid five or more new studies per day on average in the gene-editing field.

You manage safety through specific technical procedures:

• Use computer algorithms to probe the genome and select new target regions if potential off-target sequences are too high.
• Perform empirical testing by exhaustively testing related DNA sequences in cultured cells before clinical trials.
• Engineer CRISPR proteins by swapping amino acids to develop higher-fidelity versions with reduced off-target activity.
• Fine-tune the dosage of Cas9 and guide RNA to ensure target editing without excess lingering molecules.

Scientists must transparently guide the public and voluntarily pause heritable human genome modifications until societal consensus is reached. The participants of the Napa Valley forum published a perspective in Science outlining four key recommendations. On March 19, 2015, the article titled A Prudent Path Forward for Genomic Engineering and Germline Gene Modification was published online in Science.

You engage the broader community through coordinated actions:

• Create forums allowing interested members of the public to access reliable information about new gene-editing technologies, their risks, rewards, and implications.
• Continue testing and developing CRISPR technology in cultured human cells and nonhuman animal models to understand safety profiles.
• Convene an international meeting to ensure safety and ethical implications are openly discussed among diverse stakeholders.
• Refrain from attempting to make heritable changes to the human genome until governments and societies consider the issue.

10 Key Ideas

1. Humanity is shifting from the passive subject of blind evolution to the active architect of biological destiny through powerful new gene-editing tools.
2. Curiosity-driven research into bacterial immune systems unexpectedly unlocked programmable molecular scissors known as CRISPR-Cas9 for revolutionary genome engineering.
3. Bacteria use CRISPR arrays as a molecular vaccination card by storing memories of past viral infections to recognize and destroy invading phages.
4. By combining Cas9 with tracrRNA and CRISPR RNA into a single-guide RNA, researchers transformed a natural defense system into a programmable gene-cutting tool.
5. CRISPR-Cas9 can precisely target and repair specific disease-causing genetic mutations in human cells, such as the single-letter mutation responsible for sickle cell disease.
6. Gene editing revolutionizes agriculture, livestock breeding, and biomedical models by offering precise mutagenesis, disease resistance, and revolutionary gene drives without foreign DNA.
7. CRISPR gene drives bypass standard inheritance laws to autonomously copy themselves and spread specific genetic traits through wild populations at exponential rates.
8. Because natural Cas9 can occasionally make off-target cuts at mismatched DNA sequences, scientists must use computational, empirical, and protein-engineering strategies to ensure safety.
9. Scientists must transparently guide the public and voluntarily pause heritable human genome modifications until societal consensus is reached.
10. The broader community must engage in coordinated actions to ensure safety and ethical implications are openly discussed among diverse stakeholders before attempting heritable changes.